Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond

Translational Lung Cancer Research

Volumn 4, Issue 2, 2015, Pages 126-141

  Khoo, Christine ^a   Rogers, Toni Maree ^a   Fellowes, Andrew ^a   Bell, Anthony ^a   Fox, Stephen ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anaplastic lymphoma kinase (ALK); Epidermal growth factor receptor (EGFR); RET; ROS1

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN RET; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE ROS1; UNCLASSIFIED DRUG;

CLINICAL LABORATORY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETIC SCREENING; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SANGER SEQUENCING; SOMATIC MUTATION; WORKFLOW;

EID: 84942085066     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2015.01.10     Document Type: Review

References (70)

1. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-51.
2. Midthun DE. Available online: http://www.uptodate.com/contents/overview-of-the-risk-factors-pathologyand-clinical-manifestations-of-lung-cancer?source=machineLearning&search=lung+cancer&selectedTitle=1%7E150§ionRank=1&anchor=H8#H8. [Accessed on Jan 13, 2014].
3. Vnencak-Jones CL, Berger MF, Pao W. Types of Molecular Tumor Testing. My Cancer Genome 2014. Available online: http://www.mycancergenome.org/content/molecular-medicine/types-of-molecular-tumortesting. [Accessed on Aug 8, 2014].
4. Cagle PT, Sholl LM, Lindeman NI, et al. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non-Small Cell Carcinoma of the Lung. Available online: http://www.cap.org/ShowProperty?nodePath=/UCMCon/ContributionFolders/WebContent/pdf/lungbiomarker-13template-1100.pdf
5. Cancer Protocols. Available online: http://www.rcpa.edu.au/Library/Practising-Pathology/Structured-Pathology-Reporting-of-Cancer/Cancer-Protocols
6. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013;15:415-53.
7. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50.
8. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
10. Yu HA, Riely GJ. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J Natl Compr Canc Netw 2013;11:161-9.
11. Stasi I, Cappuzzo F. Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Transl Respir Med 2014;2:2.
12. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
13. Kadota K, Yeh YC, D'Angelo SP, et al. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation. Am J Surg Pathol 2014;38:1118-27.
14. Scholl LM, Lindeman NI. Molecular Pathology of Lung Cancers. In: Cheng L, Eble JN. eds. Molecular Surgical Pathology. First Edition 2013:83-94.
15. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013;31:3987-96.
16. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773-80.
17. Fang DD, Zhang B, Gu Q, et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol 2014;9:285-94.
18. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PloS One 2012;7:e31323.
19. Majewski IJ, Mittempergher L, Davidson NM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013;230:270-6.
20. Jung Y, Kim P, Jung Y, et al. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. Genes Chromosomes Cancer 2012;51:590-7.
21. Esfahani K, Agulnik JS, Cohen V. A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol 2014;4:174.
22. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013;19:4040-5.
23. Lee SE, Lee B, Hong M, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 2014. [Epub ahead of print].
24. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
25. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
26. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554-62.
27. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in nonsmall cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18:4449-57.
28. Suehara Y, Arcila M, Wang L, et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNAbased screen for tyrosine kinase fusions. Clin Cancer Res 2012;18:6599-608.
29. Yoshida A, Tsuta K, Wakai S, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 2014;27:711-20.
30. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and neversmokers. Cell 2012;150:1121-34.
31. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. N Engl J Med 2014;371:1963-71.
32. Kohno T, Tsuta K, Tsuchihara K, et al. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci 2013;104:1396-400.
33. Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
34. Chao BH, Briesewitz R, Villalona-Calero MA. RET fusion genes in non-small-cell lung cancer. J Clin Oncol 2012;30:4439-41.
35. Gainor JF, Shaw AT. The new kid on the block: RET in lung cancer. Cancer Discov 2013;3:604-6.
36. Dacic S. Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. J Clin Pathol 2013;66:870-4.
37. Wong SQ, Li J, Tan AY, et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics 2014;7:23.
38. Wong SQ, Li J, Salemi R, et al. Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. Sci Rep 2013;3:3494.
39. Sah S, Chen L, Houghton J, et al. Functional DNA quantification guides accurate next-generation sequencing mutation detection in formalin-fixed, paraffin-embedded tumor biopsies. Genome Med 2013;5:77.
40. Ellison G, Zhu G, Moulis A, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol 2013;66:79-89.
41. Archer™ ALK, RET, ROS1 v2 Panel. Enzymatics;2014. [cited 2014 Dec 1]. Available online: http://www.enzymatics.com/wp-content/uploads/2014/01/Archer_Brochure_2014.pdf
42. Best DH, Swensen JJ. Molecular Genetics and Personalized Medicine: Humana Press, 2012:1-50.
43. Li T, Kung HJ, Mack PC, et al. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31:1039-49.
44. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto Calif) 2013;6:287-303.
45. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008;9:387-402.
46. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011;32:177-95.
47. Salto-Tellez M, Gonzalez de Castro D. Next-generation sequencing: a change of paradigm in molecular diagnostic validation. J Pathol 2014;234:5-10.
48. Pearce M, Nakorchevsky A, Nygren A, et al. Targeted Mutation Profiling of Non-Small Cell Lung Cancer Samples using the Sequenom Lungcarta™ Panel* for Clinical Research. Sequenom;2014. [cited 2014 Oct 18]. Available online: http://www.genehk.com/news/doc/LungCarta%20Application%20Note.pdf
49. Available online: http://agenabio.com/sites/default/files/41-20013R1.0-LungCarta-Flyer.pdf
50. FDA. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). Available online: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm
51. cobas® EGFR Mutation Test for in vitro diagnostic use. Roche Molecular Systems Inc., 2013. Available online: http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120019c.pdf
52. therascreen® EGFR RGQ PCR Kit Instructions for Use (Handbook), 2013. Available online: http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120022c.pdf
53. Storm N, Darnhofer-Patel B, van den Boom D, et al. MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol 2003;212:241-62.
54. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
55. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-34.
56. Fukuoka M, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. J Clin Oncol 2011;29:2866-74.
57. Cooper W, Fox S, O'Toole S, et al. National Working Group Meeting on ALK diagnostics in lung cancer. Asia Pac J Clin Oncol 2014;10 Suppl 2:11-17.
58. Shaw AT, Solomon B, Kenudson MM. Crizotinib and testing for ALK. J Natl Compr Canc Netw 2011;9:1335-41.
59. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012;461:245-57.
60. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2013;26:1545-53.
61. Hutarew G, Hauser-Kronberger C, Strasser F, et al. Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: evaluation of five different ALK antibody clones and ALK FISH. Histopathology 2014;65:398-407.
62. Towne P, McElhinny A, Nitta H, et al. VENTANA ALK Scoring Interpretation Guide for nonsmall cell lung carcinoma (NSCLC). Germany: Ventana Medical Systems, Inc. and Roche Diagnostics International, Inc;2012-2013 [cited 2014 Sept 17]. Available online: http://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=7&ved=0CEgQFjAG&url=http%3A%2F%2Fwww.uclad.com%2Fnewsletters%2FALK-LUNG-IHCINTERPRETATION-GUIDE.pdf&ei=2okBVeanDMPDmAWTuIGYAw&usg=AFQjCNEG-3eETtqQq_dcgvIfmSDK4rrJYQ&bvm=bv.87920726,d.dGY
63. ESP Lung External Quality Assessment Scheme. Available online: http://lung.eqascheme.org/. [Accessed on Aug 24, 2014].
64. Cooper WA, Yu B, Yip PY, et al. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma. J Clin Pathol 2013;66:744-8.
65. Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 2010;12:169-76.
66. Lira ME, Kim TM, Huang D, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013;15:51-61.
67. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275-83.
68. Lira ME, Choi YL, Lim SM, et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn 2014;16:229-43.
69. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
70. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 2014;4:650-61.